Molecular Diagnostics
British Journal of Cancer (2005) 92, 1493–1498. doi:10.1038/sj.bjc.6602503 www.bjcancer.com
Published online 5 April 2005
Somatostatin receptors 2 and 5 are preferentially expressed in proliferating endothelium
R L Adams1, I P Adams1, S W Lindow2, W Zhong1 and S L Atkin1
- 1Endocrinology Research Group, Division of Academic Medicine, University of Hull Postgraduate Medical School, Hull HU6 7RX, UK
- 2Department of Obstetrics and Gynecology, Hull Women and Children's Hospital, Hull HU3 2JZ, UK
Correspondence: Dr SL Atkin, The Michael White Diabetes Centre, 220-236, Anlaby Road, Hull HU3 2RW, UK. E-mail: S.L.Atkin@hull.ac.uk
Received 27 May 2004; Revised 24 January 2005; Accepted 8 February 2005; Published online 5 April 2005.
Abstract
Angiogenesis is characterised by activation, migration and proliferation of endothelial cells and is central to the pathology of cancer, cardiovascular disease and chronic inflammation. Somatostatin is an inhibitory polypeptide that acts through five receptors (sst 1, 2, 3, 4, 5). Sst has previously been reported in endothelium, but their role remains obscure. Here, we report the expression of sst in human umbilical vein endothelial cells (HUVECs) in vitro, during proliferation and quiescence. A protocol for culturing proliferating and quiescent HUVECs was established, and verified by analysing cell cycle distribution in propidium-iodide-stained samples using flow cytometry. Sst mRNA was then quantified in nine proliferating and quiescent HUVEC lines using quantitative reverse transcriptase–polymerase chain reaction. Sst 2 and 5 were preferentially expressed in proliferating HUVECs. All samples were negative for sst 4. Sst 1 and 3 expression and cell cycle progression were unrelated. Immunostaining for sst 2 and 5 showed positivity in proliferating but not quiescent cells, confirming sst 2 and 5 protein expression. Inhibition of proliferating cells with somatostatin analogues Octreotide and SOM230, which have sst 5 activity, was found (Octreotide 10-10–10-6 M: 48.5–70.2% inhibition; SOM230 10-9–10-6 M: 44.9–65.4% inhibition) in a dose-dependent manner, suggesting that sst 5 may have functional activity in proliferation. Dynamic changes in sst 2 and 5 expression during the cell cycle and the inhibition of proliferation with specific analogues suggest that these receptors may have a role in angiogenesis.
Keywords:
somatostatin receptors, endothelium, angiogenesis, proliferation, Octreotide, SOM230
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Opportunities in somatostatin research: biological, chemical and therapeutic aspects
Nature Reviews Drug Discovery Review (01 Dec 2003)
Molecular targets in pituitary tumours
Nature Reviews Cancer Review (01 Apr 2004)
RESEARCH
British Journal of Cancer Scientific Correspondence
Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour
British Journal of Cancer Original Article
Prostate Cancer and Prostatic Diseases Original Article
